Related Experiment Videos
[Initial experiences with methylene blue virus inactivated fresh frozen plasma: results of a clinical and in vitro
1Abteilung für Transfusionsmedizin, Universitätskliniken Göttingen.
Abstract:
Methylene blue (MB) has recently been introduced to inactivate viruses in single donor fresh frozen plasma (FFP) units. In the first clinical study 519 units of MB-treated FFP were given to 103 patients. No specific clinical side effects with adverse reactions were recorded. However, after thawing, clots were observed in 9 of the first 110 units, although the medical staff had thawed the MB-FFP in exactly the same manner as the conventional FFP in which clots are extremely rare. The possible effects of methylene blue were investigated by subsequent in vitro experiments: Methylene blue together with light led to generation of fibrin(ogen) derivatives which have an increased tendency for aggregation but cannot be normally clotted by thrombin and even seem to interfere with normal fibrin polymerization. Inadequate conditions during plasma preparation such as long illumination or temperatures above 40 degrees C enhanced the generation of these fibrin(ogen)-derivatives. In addition, special requirements for producers and users of MB-FFP and further investigations are necessary in order to prevent complications.
Insights
Methylene blue (MB) treatment for fresh frozen plasma (FFP) showed no immediate side effects in patients. However, in vitro studies revealed MB and light can create abnormal fibrin derivatives, potentially causing clotting issues.
Area of Science:
- Biochemistry
- Hematology
- Blood Product Safety
Context:
- Methylene blue (MB) is a novel agent for virus inactivation in fresh frozen plasma (FFP).
- Initial clinical trials involved 519 units of MB-treated FFP administered to 103 patients without observed adverse reactions.
- A complication of clot formation was noted in a subset of thawed MB-FFP units, distinct from conventional FFP.
Purpose:
- To investigate the potential adverse effects of methylene blue treatment on fresh frozen plasma.
- To elucidate the mechanism behind clot formation observed in MB-treated FFP post-thawing.
- To identify factors influencing the generation of aberrant fibrin derivatives in MB-FFP.
Summary:
- In vitro experiments demonstrated that methylene blue in conjunction with light exposure generates fibrin(ogen) derivatives.
- These derivatives exhibit increased aggregation tendencies and impaired thrombin-induced clotting, interfering with normal fibrin polymerization.
- Suboptimal plasma preparation conditions, including prolonged illumination and temperatures exceeding 40°C, exacerbate the formation of these derivatives.
Impact:
- Highlights the need for specific handling and preparation protocols for MB-FFP to mitigate clotting complications.
- Suggests further research is required to fully understand and prevent adverse events associated with MB-treated plasma.
- Informs manufacturers and clinicians about potential risks and necessary precautions when using methylene blue for plasma pathogen reduction.